Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice

Journal of Experimental and Clinical Cancer Research

Volumn 35, Issue 1, 2016, Pages

  Kong, Lingxiang ^a   Zhou, Yongjie ^a,b   Bu, Hong ^a,b   Lv, Tao ^a   Shi, Yujun ^a   Yang, Jiayin ^a  

^a SICHUAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma (HCC); Inflammation; Interleukin 6 (IL 6); Tumor associated macrophage (TAM)

Indexed keywords

INTERLEUKIN 6; STAT3 PROTEIN; ABC TRANSPORTER SUBFAMILY B; IL6 PROTEIN, HUMAN; INTERLEUKIN-6, MOUSE; P-GLYCOPROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL FUNCTION; CELL INFILTRATION; CELL LOSS; CONTROLLED STUDY; GAMMA RADIATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER HOMOGENATE; LIVER TOXICITY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; STAINING; UPREGULATION; ADULT; AGED; ANIMAL; BLOOD; DEFICIENCY; EXPERIMENTAL NEOPLASM; FEMALE; GENE DELETION; GENETICS; IMMUNOLOGY; KUPFFER CELL; LEUKOCYTE COUNT; LIVER TUMOR; MALE; MIDDLE AGED;

ADULT; AGED; ANIMALS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY B; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE DELETION; HUMANS; INTERLEUKIN-6; KUPFFER CELLS; LEUKOCYTE COUNT; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL;

EID: 84984986358     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-016-0412-1     Document Type: Article

References (46)

1. Garancini M, Pinotti E, Nespoli S, et al. Hepatic resection beyond barcelona clinic liver cancer indication: when and how. World J Hepatol. 2016;8:513-9.
2. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99.
3. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008;9:628-38.
4. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 2001;85:473-83.
5. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
6. Imperial JC. Natural history of chronic hepatitis B and C. J Gastroenterol Hepatol. 1999;14 Suppl:S1 - 5.
7. Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol. 2015;10:345-70.
8. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053-63.
9. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-12.
10. Porta C, Larghi P, Rimoldi M, et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology. 2009;214:761-77.
11. Walbrun P, Hellerbrand C, Weiss TS, et al. Characterization of rat and human Kupffer cells after cryopreservation. Cryobiology. 2007;54:164-72.
12. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
13. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231-7.
14. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends In Immunology. 2002;23:549-55.
15. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204.
16. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502-12.
17. Tacke RS, Tosello-Trampont A, Nguyen V, et al. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem. 2011;286:10847-55.
18. Kao JT, Lai HC, Tsai SM, et al. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naive hepatitis B infection patients. Liver Int. 2012;32:928-36.
19. Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987;84:7251-5.
20. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-54.
21. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297-314.
22. Johnson C, Han Y, Hughart N, et al. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1:58-70.
23. Blindenbacher A, Wang X, Langer I, et al. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology. 2003;38:674-82.
24. Tiberio GA, Tiberio L, Benetti A, et al. IL-6 Promotes compensatory liver regeneration in cirrhotic rat after partial hepatectomy. Cytokine. 2008;42:372-8.
25. Streetz KL, Tacke F, Leifeld L, et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology. 2003;38:218-29.
26. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008;103:1372-9.
27. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-34.
28. Hsia CY, Huo TI, Chiang SY, et al. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol. 2007;33:208-12.
29. Mauad TH, van Nieuwkerk CM, Dingemans KP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol. 1994;145:1237-45.
30. Di JZ, Han XD, Gu WY, et al. Association of hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an increased risk of hepatocellular carcinoma. J Zhejiang Univ Sci B. 2011;12:805-11.
31. Yan L, Zhu T, Sun T, et al. Activation of calcium-sensing receptors is associated with apoptosis in a model of simulated cardiomyocytes ischemia/reperfusion. J Biomed Res. 2010;24:301-7.
32. Kinoshita M, Uchida T, Nakashima H, et al. Opposite effects of enhanced tumor necrosis factor-alpha production from Kupffer cells by gadolinium chloride on liver injury/mortality in endotoxemia of normal and partially hepatectomized mice. Shock. 2005;23:65-72.
33. Harstad EB, Klaassen CD. Gadolinium chloride pretreatment prevents cadmium chloride-induced liver damage in both wild-type and MT-null mice. Toxicol Appl Pharmacol. 2002;180:178-85.
34. Badger DA, Kuester RK, Sauer JM, et al. Gadolinium chloride reduces cytochrome P450: relevance to chemical-induced hepatotoxicity. Toxicology. 1997;121:143-53.
35. Xu DX, Wei W, Sun MF, et al. Kupffer cells and reactive oxygen species partially mediate lipopolysaccharide-induced downregulation of nuclear receptor pregnane x receptor and its target gene CYP3a in mouse liver. Free Radic Biol Med. 2004;37:10-22.
36. Bradshaw G, Gutierrez A, Miyake JH, et al. Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice. Proc Natl Acad Sci U S A. 2005;102:11029-34.
37. Chung KY, Jeong GY, Choi KB, et al. Prevention of primary nonfunction after canine liver allotransplantation: the effect of gadolinium chloride. Transplant Proc. 2004;36:1928-30.
38. Kovalovich K, DeAngelis RA, Li W, et al. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology. 2000;31:149-59.
39. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766-70.
40. Ataseven H, Bahcecioglu IH, Kuzu N, et al. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediat Inflamm. 2006;2006:78380.
41. Barash H, R Gross E, Edrei Y, et al. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A. 2010;107:2207-12.
42. Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer. 2014;120:2824-38.
43. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798-809.
44. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197-208.
45. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell. 2008;13:7-9.
46. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009;15:79-80.